Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Neurological Diseases Have No Cures
- Worldwide Neurology Markets
- Major Neurology Franchises
- Business Strategies-2006
- Ten Largest Neurology Deals, 2005-2006
- Mergers & Acquisitions (M&As)
- Protecting a Market-Leading Multiple Sclerosis Franchise
- Risk Management of ƒ¿4-Integrin Inhibitors
- BG-12
- Extending Reach from Generics to Branded Pharmaceuticals
- Sanofi-Aventis/Teva' s Copaxone
- Teva/Lundbeck' s Azilect (rasagiline)
- Filling a Neurology Pipeline Through Acquisitions and Inlicensing
- Fully Integrated Companies
- Challenges from Generics and Biogenerics/Biosimilars Encroachment
- Sidebar: Demise of the Instant Fully Integrated Pharmaceutical Company
(FIPCO) Strategy
- Life-Cycle Management
- Fixed Combinations in Parkinson' s Disease
- Expanding Disease Indications
- Rituxan/MabThera
- Zenapax (daclizumab)
- Campath/MabCampath (alemtuzumab)
- Reformulations
- Serono' s Rebif
- Eisai/Pfizer' s Aricept
- Where Is the Innovation?
- Resource Allocation and Prioritization
- Disease-Causing Genes and Biomarkers
- Parkinson' s Disease
- Alzheimer' s Disease
- Epilepsy
- Using Pharmacogenomics to Create Personalized Medicines
- What' s Going on With Stem Cells?
- Outlook
Figures
- 1. Worldwide Markets for Four Major Neurology Diseases, 2004/2005
- 2. Prevalence of Four Major Neurology Diseases, 2004/2005
- 3. Major Worldwide Neurology Franchises, 2005
- 4. Largest Neurology Deals, 2005-2006
Tables
- 1. Top Ten Neurology Brands
- 2. Select Neurology-Based Mergers and Acquisitions, 2005-2006
- 3. Strengthening Eisai' s Neurology Franchise Through Product Acquisitions
and Licensing
- 4. Life-Cycle Management of Select Neurology Drugs
- 5. Extending Disease Indications for Existing Monoclonal Antibodies
- 6. Genes Associated with Parkinson' s Disease
- 7. Neurology Drugs in Phase III Development or Later, 2006
|
Related Report
|
View Cart
